Literature DB >> 1696236

Cellular hypersensitivity to a synthetic dodecapeptide derived from human adenovirus 12 which resembles a sequence of A-gliadin in patients with coeliac disease.

G J Mantzaris1, J A Karagiannis, J D Priddle, D P Jewell.   

Abstract

The human intestinal adenovirus serotype 12 (Ad12) may be implicated in the pathogenesis of coeliac disease by virtue of immunological cross reactivity between epitopes shared by its early region E1b protein and A-gliadin. In the present study a synthetic dodecapeptide from the corresponding viral epitope (Ad12E1b, residues 384-395) was tested for its effect on peripheral blood mononuclear cells from 22 treated and eight untreated patients with coeliac disease, 22 healthy subjects, 11 patients with ulcerative colitis, and 11 patients with Crohn's disease by an indirect leucocyte migration inhibition assay. In addition, the effect of both the viral and the gliadin synthetic peptides was studied by proliferation and migration assays simultaneously performed in an unselected subgroup of 12 treated coeliac patients and 12 healthy subjects of the study. Coeliac patients with untreated disease showed no response to the viral peptide compared with treated patients (p greater than 0.1). Treated coeliac patients showed a significantly different response from healthy control subjects and control patients with disease (p less than 0.001) which was dependent on the concentration of the viral peptide. In the subgroup of the treated coeliac patients (n = 12) there was a significant correlation between the responses in the migration and the proliferation assay using either the viral (p less than 0.02) or the gliadin (p less than 0.005) peptide at the highest concentration (33.3 micrograms/ml). Furthermore, the responses obtained using viral peptide correlated significantly with the responses obtained with gliadin peptide in both the migration (p less than 0.001) and the proliferation (p less than 0.001) assays. These results show that in coeliac patients there is pronounced cross reactivity at the level of T cell recognition between synthetic peptides derived from the Ad12 and A-gliadin. This antigenic cross reactivity may be involved in the pathogenesis of coeliac disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696236      PMCID: PMC1378493          DOI: 10.1136/gut.31.6.668

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Cell-mediated immunity to gluten fraction III in adult coeliac disease.

Authors:  G K Holmes; P Asquith; W T Cooke
Journal:  Clin Exp Immunol       Date:  1976-05       Impact factor: 4.330

2.  Effect of gluten supplementation in healthy siblings of children with celiac disease.

Authors:  I Polanco; M L Mearin; J Larrauri; I Biemond; A Wipkink-Bakker; A S Peña
Journal:  Gastroenterology       Date:  1987-03       Impact factor: 22.682

3.  HLA-B8 and cell-mediated immunity to gluten.

Authors:  F G Simpson; A W Bullen; D A Robertson; M S Losowsky
Journal:  Gut       Date:  1981-08       Impact factor: 23.059

4.  Coeliac disease in monozygotic twins.

Authors:  D J Shale; D G Johnston; R Hall; D F Roberts
Journal:  Postgrad Med J       Date:  1982-12       Impact factor: 2.401

5.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

6.  Cellular response to alpha-gliadin in untreated coeliac disease.

Authors:  C O'Farrelly; C Feighery; J F Greally; D G Weir
Journal:  Gut       Date:  1982-01       Impact factor: 23.059

Review 7.  Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture.

Authors:  P I Terasaki; D Bernoco; M S Park; G Ozturk; Y Iwaki
Journal:  Am J Clin Pathol       Date:  1978-02       Impact factor: 2.493

8.  Stimulation of lymphocytes from patients with coeliac disease by a subfraction of gluten.

Authors:  K Sikora; B S Anand; S C Truelove; P J Ciclitira; R E Offord
Journal:  Lancet       Date:  1976-08-21       Impact factor: 79.321

9.  Nucleic acid (cDNA) and amino acid sequences of alpha-type gliadins from wheat (Triticum aestivum).

Authors:  D D Kasarda; T W Okita; J E Bernardin; P A Baecker; C C Nimmo; E J Lew; M D Dietler; F C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  HLA-DR phenotypes in Spanish coeliac children: their contribution to the understanding of the genetics of the disease.

Authors:  M L Mearin; I Biemond; A S Peña; I Polanco; C Vazquez; G T Schreuder; R R de Vries; J J van Rood
Journal:  Gut       Date:  1983-06       Impact factor: 23.059

View more
  7 in total

Review 1.  Molecular biology and coeliac disease.

Authors:  P D Howdle; G E Blair
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

Review 2.  Cereal chemistry, molecular biology, and toxicity in coeliac disease.

Authors:  R P Sturgess; H J Ellis; P J Ciclitira
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Is persistent adenovirus 12 infection involved in coeliac disease? A search for viral DNA using the polymerase chain reaction.

Authors:  J Mahon; G E Blair; G M Wood; B B Scott; M S Losowsky; P D Howdle
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

4.  Molecular biology of coeliac disease.

Authors:  R Tighe; P J Ciclitira
Journal:  Arch Dis Child       Date:  1995-09       Impact factor: 3.791

5.  Coeliac disease: characterisation of monoclonal antibodies raised against a synthetic peptide corresponding to amino acid residues 206-217 of A-gliadin.

Authors:  H J Ellis; A P Doyle; R P Sturgess; P J Ciclitira
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

Review 6.  Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?

Authors:  Emanuel Pusch; Harald Renz; Chrysanthi Skevaki
Journal:  Allergo J Int       Date:  2018-03-26

Review 7.  Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?

Authors:  Emanuel Pusch; Harald Renz; Chrysanthi Skevaki
Journal:  Allergo J       Date:  2018-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.